CA2673260A1 - Compositions de facteur vii et viia - Google Patents

Compositions de facteur vii et viia Download PDF

Info

Publication number
CA2673260A1
CA2673260A1 CA002673260A CA2673260A CA2673260A1 CA 2673260 A1 CA2673260 A1 CA 2673260A1 CA 002673260 A CA002673260 A CA 002673260A CA 2673260 A CA2673260 A CA 2673260A CA 2673260 A1 CA2673260 A1 CA 2673260A1
Authority
CA
Canada
Prior art keywords
composition
fvii
polypeptide
fviia
reconstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002673260A
Other languages
English (en)
Inventor
Thomas Joergensen
Joern Drustrup
Kim Vilbour Andersen
Hanns-Christian Mahler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2673260A1 publication Critical patent/CA2673260A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA002673260A 2006-12-20 2007-12-18 Compositions de facteur vii et viia Abandoned CA2673260A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87094806P 2006-12-20 2006-12-20
US60/870,948 2006-12-20
PCT/IB2007/004338 WO2008078189A2 (fr) 2006-12-20 2007-12-18 Compositions de facteur vii et viia

Publications (1)

Publication Number Publication Date
CA2673260A1 true CA2673260A1 (fr) 2008-07-03

Family

ID=39431180

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002673260A Abandoned CA2673260A1 (fr) 2006-12-20 2007-12-18 Compositions de facteur vii et viia

Country Status (4)

Country Link
EP (1) EP2114379A2 (fr)
JP (1) JP2010513462A (fr)
CA (1) CA2673260A1 (fr)
WO (1) WO2008078189A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子vii多肽和其用途
HUE049023T2 (hu) * 2008-08-15 2020-08-28 Ironwood Pharmaceuticals Inc Linaklotidot tartalmazó, szájon át történõ beadásra szolgáló készítmények
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
WO2011017502A2 (fr) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprenant du linaclotide
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
RS59978B1 (sr) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
AR083035A1 (es) * 2010-09-17 2013-01-30 Baxter Int ESTABILIZACION DE INMUNOGLOBULINAS MEDIANTE UNA FORMULACION ACUOSA CON HISTIDINA A pH ACIDO DEBIL A NEUTRO, COMPOSICION ACUOSA DE INMUNOGLOBULINA
ES2369945B1 (es) 2011-07-29 2012-10-15 Eduardo Anitua Aldecoa Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento.
DK2776055T3 (en) 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
KR102058864B1 (ko) 2013-12-16 2019-12-24 주식회사 티움바이오 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
MX2016013667A (es) * 2014-04-28 2017-01-23 Eisai R&D Man Co Ltd Formulacion liofilizada de factor de crecimiento hepatico (hgf).
US11548926B2 (en) 2016-03-17 2023-01-10 Eisai R&D Management Co., Ltd. Method for producing an active hepatocyte growth factor (HGF)
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
SI1499719T1 (sl) * 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
EP1517698B2 (fr) * 2002-06-21 2017-12-06 Novo Nordisk Health Care AG COMPOSITIONS SOLIDES STABILISEES DE POLYPEPTIDES DE FACTEUR VIIa
US20060166874A1 (en) * 2002-09-30 2006-07-27 Haaning Jesper M Fvii or fviia variants having increased clotting activity
EP2298287B1 (fr) * 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Compositions stabilisees de polypeptides de facteur VII

Also Published As

Publication number Publication date
EP2114379A2 (fr) 2009-11-11
WO2008078189A3 (fr) 2009-03-05
JP2010513462A (ja) 2010-04-30
WO2008078189A2 (fr) 2008-07-03

Similar Documents

Publication Publication Date Title
CA2673260A1 (fr) Compositions de facteur vii et viia
JP4879104B2 (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ix処方
ES2449224T3 (es) Administración subcutánea del Factor de coagulación VII
KR101212025B1 (ko) 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
US20090017007A1 (en) Liquid factor vii composition
US11633462B2 (en) Pharmaceutical composition comprising plasminogen and uses thereof
JP3537440B2 (ja) 可溶性トロンボモジュリンを長期保存安定化させる方法
US6204036B1 (en) Stable transglutaminase preparations and processes for their production
FI85335C (fi) Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition.
US9968662B2 (en) Factor VII composition
KR20010020325A (ko) 활성 단백질 c 제제
US20230414698A1 (en) Collagen 7 compositions and methods of using the same
KR20040065278A (ko) 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US10391062B2 (en) Dry transglutaminase composition
JP6029674B2 (ja) 第viii因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
KR101006070B1 (ko) 인자 ⅶ 폴리펩티드의 액체 조성물
WO2023246680A1 (fr) Activateurs du facteur de coagulation x et formulations de ceux-ci pour le traitement de troubles hémorragiques

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121218

FZDE Dead

Effective date: 20151008